Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6233 | 1446 | 23.3 | 68% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
434 | 15650 | CHEMOTHERAPY-TOKYO//JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY//CEFEPIME |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | DORIPENEM | Author keyword | 82 | 66% | 5% | 76 |
2 | ERTAPENEM | Author keyword | 71 | 52% | 7% | 97 |
3 | MEROPENEM | Author keyword | 41 | 28% | 9% | 125 |
4 | BIAPENEM | Author keyword | 23 | 72% | 1% | 18 |
5 | CARBAPENEM | Author keyword | 15 | 20% | 5% | 67 |
6 | IMIPENEM | Author keyword | 12 | 16% | 5% | 66 |
7 | CARBAPENEMS | Author keyword | 11 | 16% | 4% | 65 |
8 | FAROPENEM | Author keyword | 9 | 48% | 1% | 14 |
9 | PANIPENEM | Author keyword | 8 | 56% | 1% | 10 |
10 | CLIN PHARMACOTHER Y | Address | 7 | 27% | 1% | 21 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | DORIPENEM | 82 | 66% | 5% | 76 | Search DORIPENEM | Search DORIPENEM |
2 | ERTAPENEM | 71 | 52% | 7% | 97 | Search ERTAPENEM | Search ERTAPENEM |
3 | MEROPENEM | 41 | 28% | 9% | 125 | Search MEROPENEM | Search MEROPENEM |
4 | BIAPENEM | 23 | 72% | 1% | 18 | Search BIAPENEM | Search BIAPENEM |
5 | CARBAPENEM | 15 | 20% | 5% | 67 | Search CARBAPENEM | Search CARBAPENEM |
6 | IMIPENEM | 12 | 16% | 5% | 66 | Search IMIPENEM | Search IMIPENEM |
7 | CARBAPENEMS | 11 | 16% | 4% | 65 | Search CARBAPENEMS | Search CARBAPENEMS |
8 | FAROPENEM | 9 | 48% | 1% | 14 | Search FAROPENEM | Search FAROPENEM |
9 | PANIPENEM | 8 | 56% | 1% | 10 | Search PANIPENEM | Search PANIPENEM |
10 | IMIPENEM CILASTATIN | 5 | 28% | 1% | 16 | Search IMIPENEM+CILASTATIN | Search IMIPENEM+CILASTATIN |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | S 4661 | 66 | 83% | 3% | 38 |
2 | CARBAPENEM | 64 | 41% | 8% | 122 |
3 | MK 0826 | 61 | 76% | 3% | 42 |
4 | L 749 345 | 52 | 87% | 2% | 26 |
5 | DEHYDROPEPTIDASE I | 46 | 56% | 4% | 56 |
6 | SM 7338 | 46 | 67% | 3% | 41 |
7 | LJC10 627 | 32 | 88% | 1% | 15 |
8 | PARENTERAL CARBAPENEM | 30 | 79% | 1% | 19 |
9 | IMIPENEM CILASTATIN | 29 | 25% | 7% | 101 |
10 | MEROPENEM | 28 | 23% | 7% | 108 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Comparative review of the carbapenems | 2007 | 170 | 97 | 73% |
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence | 2012 | 14 | 12 | 75% |
The risk of seizures among the carbapenems: a meta-analysis | 2014 | 3 | 81 | 58% |
Doripenem Monohydrate, A Broad-Spectrum Carbapenem Antibiotic | 2009 | 36 | 67 | 76% |
Doripenem | 2009 | 37 | 39 | 64% |
Carbapenems | 2013 | 8 | 143 | 66% |
Comparative pharmacokinetics of the carbapenems - Clinical implications | 2000 | 101 | 115 | 53% |
Carbapenems: Past, Present, and Future | 2011 | 106 | 223 | 13% |
Selective determination of ertapenem in the presence of its degradation product | 2009 | 11 | 20 | 100% |
Epileptogenic Potential of Carbapenem Agents: Mechanism of Action, Seizure Rates, and Clinical Considerations | 2011 | 14 | 96 | 61% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLIN PHARMACOTHER Y | 7 | 27% | 1.5% | 21 |
2 | BIOL VET BIOQUIM BIOL MOLEC | 6 | 100% | 0.3% | 4 |
3 | MOL CRYSTALS | 2 | 36% | 0.3% | 4 |
4 | TANAKA | 1 | 100% | 0.1% | 2 |
5 | AFDELING MED MICROBIOL INFECTIEZIEKTEN | 1 | 50% | 0.1% | 1 |
6 | CENTLIM 03 | 1 | 50% | 0.1% | 1 |
7 | CHEM INFECT DIS | 1 | 50% | 0.1% | 1 |
8 | CHICAGO INFECT DIS | 1 | 50% | 0.1% | 1 |
9 | CITY HOSP HECKESHORN ZEHLENDORF | 1 | 50% | 0.1% | 1 |
10 | CLIN PHARM INFECT DIS | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000164620 | BURNS TRAUMA CRIT CARE//MUTANT SELECTION WINDOW//ANTIINFECT DEV |
2 | 0.0000150704 | HOIGNES SYNDROME//EEG THRESHOLD//EPILEPTOGENIC ACTIVITY |
3 | 0.0000115176 | 1 BETA METHYLCARBAPENEM//1 BETA METHYLCARBAPENEMS//5 OXACEPHAMS |
4 | 0.0000113364 | NAGZ//AMPG//AMPR |
5 | 0.0000106101 | POSTANTIBIOTIC EFFECT//POSTANTIBIOTIC SUB MIC EFFECT//POST ANTIBIOTIC EFFECT |
6 | 0.0000091836 | CFIA//BACTEROIDES FRAGILIS//NIM GENES |
7 | 0.0000085436 | TERTIARY PERITONITIS//MANNHEIM PERITONITIS INDEX//SECONDARY PERITONITIS |
8 | 0.0000077194 | CEFTAROLINE//CEFTOBIPROLE//CEFTOLOZANE TAZOBACTAM |
9 | 0.0000071006 | CEFEPIME//CEFPIROME//FK037 |
10 | 0.0000068978 | METALLO BETA LACTAMASE//METALLO BETA LACTAMASES//VIM 2 |